Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy

Hepatology

Volumn 54, Issue 1, 2011, Pages 101-108

  Hsu, Chao Wei ^a   Yeh, Chau Ting ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; ANTIGENICITY; ARTICLE; BLOOD SAMPLING; CASE REPORT; DISEASE SEVERITY; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS S GENE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MUTANT; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; SEROLOGY; SITE DIRECTED MUTAGENESIS; VIRUS GENE;

ANTIBODIES, VIRAL; BIOPSY; DNA, VIRAL; GENES, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; MUTATION; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959541653     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24363     Document Type: Article

References (33)

1. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (-)-2', 3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 267: 22414-22420.
2. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 8495-8499.
3. Severini A, Liu XY, Wilson JS, Tyrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2', 3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1995; 39: 1430-1435.
4. Xie H, Voronkov M, Liotta DC, Korba BA, Schinazi RF, Richman DD, et al. Phosphatidyl-2', 3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells. Antiviral Res 1995; 28: 113-120.
5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
6. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
7. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998; 245: 18-32.
8. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9399.
9. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180.
10. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Ducheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996; 24: 711-713.
11. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996; 24: 714-717.
12. Schalm SW. Clinical implications of lamivudine resistance by HBV. Lancet 1997; 349: 3-4.
13. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis 2010; 14: 439-459.
14. Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol 2004; 42: 4882-4884.
15. Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007; 132: 543-550.
16. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg negative chronic hepatitis B. J Hepatol 2001; 34: 306-313.
17. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
18. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
19. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. HEPATOLOGY 2000; 31: 1318-1326.
20. Parés A, Planes R, Torres M, Caballeria J, Viver JM, Acero D, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver. Results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-621.
21. Van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Center PBC Study Group. J Hepatol 1999; 31: 256-262.
22. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. HEPATOLOGY 2004; 39: 804-810.
23. Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. HEPATOLOGY 2007; 46: 1057-1070.
24. Chang MH, Hsu HY, Ni YH, Tsai KS, Lee PI, Chen PJ, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J Hepatol 1998; 28: 915-922.
25. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
26. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
27. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 1-36.
28. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
29. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 538-549.
30. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001; 8: 237-247.
31. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170.
32. Mathet VL, Cuestas ML, Ruiz V, Minassian ML, Rivero C, Trinks J, et al. Detection of hepatitis B virus (HBV) genotype E carried-even in the presence of high titers of anti-HBs antibodies-by an Argentinean patient of African descent who had received vaccination against HBV. J Clin Microbiol 2006; 44: 3435-3439.
33. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010; 15: 471-475.